pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,767 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1772Endpoints1380Fierce Biotech700BioSpace693BioPharma Dive522raps231onclive165fda recalls111
therapy area
allOncology12282Rare Disease3185Immunology2860Cardiology2724Hematology2158Pulmonology2135Vaccines
  • Medici wins Endpoints 2026 award, touts personalized cancer therapy
    Medici was announced as the winner of the Endpoints 2026 competition. The company said its approach focuses on tailoring cancer treatments to individual patients. The award highlights growing int…
    Endpoints · 1mo agoPositive↗ source
  • Endpoints 11 showcases top biotech startups, signaling renewed optimism and funding
    The Endpoints 11 awards highlight the most promising biotech startups of 2026, offering a snapshot of emerging trends in the sector. According to the summary, the awards illustrate that biotech ap…
    Endpoints · 1mo agoPositive↗ source
← prev
page 32 of 111
next →
fda medwatch109
globenewswire health73
fda press59
1787
Psychiatry & CNS1200
Ophthalmology1047
Endocrinology & Metabolism775
Pain769
Nephrology758
Indivior ends Addex PAM collaboration as it prepares for Supernus merger
Indivior Pharmaceuticals has terminated its long‑standing partnership with Addex Therapeutics that focused on developing positive allosteric modulators (PAMs) for addiction treatment. The collabor…
Fierce Biotech · 1mo agoDealNeutral↗ source
  • Kali Therapeutics pivots from Chinese drug acquisitions to focus on its own growing pipeline
    Kali Therapeutics, the winner of the Endpoints 11 2026 competition, initially explored the possibility of purchasing drug candidates from China. The company ultimately chose to rely on its own res…
    Endpoints · 1mo agoPositive↗ source
  • Stipple Bio wins Endpoints 2026 award for precision pancreatic cancer therapy
    Stipple Bio was announced as the winner of the Endpoints 2026 competition, recognized for its work in precision medicine. The company’s approach focuses on developing targeted treatments for pancr…
    Endpoints · 1mo agoPositive↗ source
  • Medra, 2026 Endpoints 11 winner, aims to build self-driving labs
    Medra, the recent winner of the Endpoints 11 2026 competition, announced plans to develop autonomous laboratory systems. The company's founder, who just completed a PhD in robotics, said the goal…
    Endpoints · 1mo agoPositive↗ source
  • Corsera wins Endpoints 11 2026 award, marking a major bet by veteran biotech leaders Meanwell and Maraganore
    Corsera was announced as the winner of the Endpoints 11 2026 competition, a recognition of its scientific progress. The win highlights the involvement of veteran biotech executives Clive Meanwell…
    Endpoints · 1mo agoPositive↗ source
  • Travere names former Amicus CEO Bradley Campbell as new leader; Roche eyes board seat for ex‑Takeda chief Alex Hoffman
    Travere Therapeutics announced that its long‑time chief executive Eric Dube will step down at the start of December, ending an almost eight‑year tenure. The board has selected Bradley Campbell, wh…
    Endpoints · 1mo agoNeutral↗ source
  • Novo signs development deal with Swedish biotech Nanexa to license long-acting delivery technology
    Novo Nordisk has entered a new development agreement with the Swedish biotech Nanexa. Under the pact, Nanexa will license its long-acting drug delivery platform to Novo, expanding the larger compa…
    Endpoints · 1mo agoDealNeutral↗ source
  • Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split
    Plus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: J&J and Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma p…
    Endpoints · 1mo agoNeutral↗ source
  • K2 Therapeutics seeks to blend China’s speed with global expertise after winning Endpoints 2026 award
    K2 Therapeutics, a small drug development company, was named the winner of the Endpoints 2026 award. The company said it will try to combine the rapid development pace found in China with its own…
    Endpoints · 1mo agoNeutral↗ source
  • Alnylam alumni lead RNAi biotech City Therapeutics to IPO filing
    Biotechs are rushing into the IPO queue. City Therapeutics submitted its public pitch late Thursday, the same night ADARx Pharmaceuticals priced its $446 million Nasdaq debut. Kendall Square-based ...
    Endpoints · 1mo ago↗ source
  • Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
    Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…
    Fierce Biotech · 1mo agoNegative readoutNegative↗ source
  • FDA advisory panel finds Grail's Galleri multicancer blood test benefits outweigh risks
    A Food and Drug Administration advisory panel voted 7-2, with one abstention, to conclude that the probable benefits of Grail's Galleri multicancer blood test outweigh its risks. The panel unanimou…
    BioPharma Dive · 1mo agoRegulatoryPositive↗ source
  • Henlius Biotech signs $440 million deal with Amberstone to develop T-cell engagers
    Henlius Biotech, a subsidiary of Fosun Pharma, announced a licensing agreement with California‑based Amberstone Biosciences valued at up to $440 million. The partnership will focus on creating anti…
    Fierce Biotech · 1mo agoDealPositive↗ source
  • Eli Lilly partners with China’s InnoCare on drug development deal worth up to $3.35 billion
    Eli Lilly has signed a partnership agreement with Beijing-based InnoCare to co-develop new medicines. InnoCare will apply its internal drug discovery platform while Lilly will contribute its devel…
    Endpoints · 1mo agoDealPositive↗ source
  • Roche signs $2 billion deal with Atavistik to discover allosteric cardiovascular-renal-metabolic drugs
    Roche announced a partnership with Cambridge-based biotech Atavistik Bio to develop allosteric small-molecule therapies for cardiovascular, renal and metabolic diseases. The agreement includes an u…
    Fierce Biotech · 1mo agoDealPositive↗ source
  • Eli Lilly commits $100M upfront in new five-target partnership with China's InnoCare
    Eli Lilly has agreed to pay $100 million upfront and in the near term to Chinese biotech InnoCare Pharma as part of a five‑target drug discovery partnership. The agreement also provides for up to $…
    Fierce Biotech · 1mo agoDealPositive↗ source
  • Merck's remigromig meets visual acuity goal in diabetic macular edema trial, safety signals noted
    Merck announced that its experimental eye drug remigromig achieved non‑inferiority to Roche’s Lucentis in a late‑stage trial for diabetic macular edema. The trial, called Brunello, measured visual…
    BioPharma Dive · 1mo agoPositive readoutNeutral↗ source
  • Roche signs discovery partnerships with Atavistik Bio and Earendil Labs
    Roche announced new collaborations with the drug discovery companies Atavistik Bio and Earendil Labs to develop early-stage candidates. The agreements continue a recent wave of dealmaking by the S…
    Endpoints · 1mo agoDealNeutral↗ source
  • Acadia’s Alzheimer’s psychosis drug misses Phase 2 goals, but moves to revised Phase 3
    Acadia Pharmaceuticals announced that its experimental treatment for psychosis linked to Alzheimer’s disease failed to meet the primary endpoints in a Phase 2 trial. The company said the data stil…
    Endpoints · 1mo agoNegative readoutNegative↗ source
  • Eli Lilly inks $3.35 B China partnership as Immunovant halts lupus drug trial
    Eli Lilly announced a new alliance with Beijing‑based InnoCare Pharma that could be worth up to $3.35 billion. The deal includes an upfront payment of $100 million and up to five target programs fo…
    BioPharma Dive · 1mo agoDealNeutral↗ source
  • Merck's $1.3B EyeBio investment yields first ophthalmology success
    Merck's strategic move to re-enter ophthalmology has begun to show results after its 2024 acquisition of EyeBio. The company committed $1.3 billion upfront for EyeBio, aiming to broaden its pipeli…
    Endpoints · 1mo agoDealPositive↗ source
  • Kyverna reports positive one-year CAR-T results for rare stiff person syndrome, supporting FDA filing
    Kyverna Therapeutics announced that its CAR-T therapy for stiff person syndrome showed positive results after one year of treatment. The trial involved patients with the rare autoimmune disorder,…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • Adagio Medical begins strategic review and cuts over half its workforce amid Nasdaq delisting risk
    Adagio Medical, a maker of cryoablation devices, announced it is launching a strategic review of its operations. As part of the review, the company will lay off more than half of its full‑time sta…
    Fierce Biotech · 1mo agoLayoffsNegative↗ source